KEVEYIS (dichlorphenamide)
CARBONIC ANHYDRASE INHIBITORS · FAMILIAL HYPERKALEMIC PERIODIC PARALYSIS ·+1
XERIS PHARMACEU
Drug class
Agents to Tx Periodic Paralysis-Carbonic Anhydrase Inhibitor
The classification phrase "Agents to Tx Periodic Paralysis-Carbonic Anhydrase Inhibitor" is an administrative and formulary subclass rather than a standalone standard pharmacological class, designating carbonic anhydrase inhibitors indicated for skeletal muscle channelopathies. Read more about Agents to Tx Periodic Paralysis-Carbonic Anhydrase Inhibitor
4 drugs in this class 4 manufacturers
Drugs in Agents to Tx Periodic Paralysis-Carbonic Anhydrase Inhibitor
ORMALVI (dichlorphenamide)
CARBONIC ANHYDRASE INHIBITORS · FAMILIAL HYPERKALEMIC PERIODIC PARALYSIS ·+1
CYCLE PHARMACEU
DICHLORPHENAMIDE
CARBONIC ANHYDRASE INHIBITORS · FAMILIAL HYPERKALEMIC PERIODIC PARALYSIS ·+1
TORRENT PHARMAC
DICHLORPHENAMIDE
CARBONIC ANHYDRASE INHIBITORS · FAMILIAL HYPERKALEMIC PERIODIC PARALYSIS ·+1
RISING PHARM
Filter & compare in the drug finder →
Opens the drug finder with Agents to Tx Periodic Paralysis-Carbonic Anhydrase Inhibitor preselected. Add indication or manufacturer filters there.
The classification phrase "Agents to Tx Periodic Paralysis-Carbonic Anhydrase Inhibitor" is an administrative and formulary subclass rather than a standalone standard pharmacological class, designating carbonic anhydrase inhibitors indicated for skeletal muscle channelopathies.
These medications, most notably dichlorphenamide and off-label acetazolamide, reversible inhibit carbonic anhydrase enzymes to induce mild systemic metabolic acidosis and modulate potassium dynamics and skeletal muscle ion channels.
Their primary therapeutic role is to reduce the frequency and severity of episodic muscle weakness in neuromuscular disorders, specifically primary hypokalemic periodic paralysis, primary hyperkalemic periodic paralysis, and related channelopathy variants.
-
fda.gov
The classification phrase "Agents to Tx Periodic Paralysis-Carbonic Anhydrase Inhibitor" is an administrative and formulary subclass rather than a standalone standard pharmacological class, designating carbonic anhydrase inhibitors indicated for skeletal muscle channelopathies These medications, most notably dichlorphenamide and off-label acetazolamide, reversible inhibit carbonic anhydrase enzymes to induce mild systemic metabolic acidosis and modulate potassium dynamics and skeletal muscle ion...
-
nih.gov
The classification phrase "Agents to Tx Periodic Paralysis-Carbonic Anhydrase Inhibitor" is an administrative and formulary subclass rather than a standalone standard pharmacological class, designating carbonic anhydrase inhibitors indicated for skeletal muscle channelopathies These medications, most notably dichlorphenamide and off-label acetazolamide, reversible inhibit carbonic anhydrase enzymes to induce mild systemic metabolic acidosis and modulate potassium dynamics and skeletal muscle ion...
-
nih.gov
These medications, most notably dichlorphenamide and off-label acetazolamide, reversible inhibit carbonic anhydrase enzymes to induce mild systemic metabolic acidosis and modulate potassium dynamics and skeletal muscle ion channels
-
nih.gov
Their primary therapeutic role is to reduce the frequency and severity of episodic muscle weakness in neuromuscular disorders, specifically primary hypokalemic periodic paralysis, primary hyperkalemic periodic paralysis, and related channelopathy variants
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.